IRAK1 and neoplasm: The “one-two punch” hypothesis that IRAK1i will both intrinsically sensitize tumor cells to RT while also allowing for RT-induced antitumor immunity to proceed (Figure 2C) is further contingent on the use of IRAK1i that are highly specific to IRAK1.